Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
57 Cards in this Set
- Front
- Back
Methotrexate Mechanism
|
Mechanism: S-phase specific antimetabolites. Folic acid analog that inhibits dihydrofolate reductase resulting in decreased dTMP and decreased DNA synthesis
|
|
Methotrexate Uses
|
Leukemias
Lymphomas Choriocarcinoma Sarcomas Abortion Ectopic Pregnancy RA Psoriasis |
|
Methotrexate Toxicity
|
Myelosupression
Macrovesicular fatty change in the liver Mucositis "Rescue with leucorvin" |
|
5 Fluorouracil Mechanism
|
S phase specific antimetabolite. Pyrimidine analog which forms 5F-dUMP which covalently complexes folic acid inhibiting thymidylate synthase.
|
|
5-Fluorouracil Uses
|
Colon Cancer and other solid tumors, topical use for basal cell carcinoma
|
|
5-Florouracil Toxicity
|
Myelosupression- which is not reversible with leucovorin
Photosensitivity Can "rescue" with thymidine |
|
6 Mercaptopurine Mechanism
|
Blocks de novo purine synthesis. Activated by HGPRTase
|
|
6 Mercaptopurine Uses
|
Leukemias, Lymphomas (not CLL or Hodgkins)
|
|
6 Mercaptopurine Toxicity
|
Bone Marrow
Liver GI Metabolized by xanthine oxidase, thus increased toxicity with allopurinol |
|
Cytarabine Mechanism
|
Inhibits DNA Polymerase
|
|
Clinical Use of Cystarbine
|
AML
|
|
Cystarabine Toxicity
|
Megaloblastic anemia
Leukopenia RThrombocytopenia |
|
Cyclophosphamide/ ifosfamide
Mechanism |
Alkylating agent- covalently links DNA at guanine N7. Drug requires bioactivation by the liver
|
|
Cyclophosphamide Clinical use
|
Non Hodgkin Lymphoma, Breast and ovarian carcinoma
|
|
Cyclophosphamide Toxicity
|
Myelosuppression
Hemorrhagic cystitisCan partial be prevented with mensa |
|
Nitrosoureas (Carmustine, lomustine, semustine, streptozocin) Mechanism
|
Alkylate DNACan Cross BBB
Requires bioactivation |
|
Nitrosoureases Uses
|
Brain Tumors
|
|
Nitrosoureas
|
CNS toxicity (dizziness, ataxia)
|
|
Cisplatin, Carboplatin Mechanism
|
Act like alkylating Agents
|
|
Cisplatin, Carboplatin Clinical Use
|
Testicular, Bladder, Ovary and lung carcinoma
|
|
Cisplatin, Carboplatin Toxicity
|
Nephrotoxicity and acustic nerve damage
|
|
Busulfan Mechanism
|
Alkylates DNA
|
|
Busulfan Use
|
CML
|
|
Busulfan Toxicity
|
Pulmonary fibrosis, hyperpigmentation
|
|
Doxorubicin, Daunorubicin Mechanism
|
Generates free radicles and non covalently intercalates DNA
|
|
Doxorubicin Uses
|
Hodgkin's and for myelomsa, sarcomas and solid tumors
|
|
Doxorubicin Toxicity
|
Cardiotoxicity
Myelosupression |
|
Dactinomycin (Actinomycin D) Mechanism
|
Intercalates DNA
|
|
Dactinomycin Uses
|
Child tumors:
Wilm's tumor Ewing's sarcoma Rhabdomyosarcoma |
|
Dactinomycin Toxicity
|
Myelosupression
|
|
Bleomycin Mechanism
|
Induces formation of free radicles
|
|
Bleomycin Uses
|
Testicular cancer, lymphomas, Hodgkins
|
|
Bleomycin Toxicity
|
Pulmonary fibrosis
Skin changes minimal myelosupression |
|
Hydroxyurea Mechanism
|
Inhibits Ribonucleotide
|
|
Hydroxyurea USes
|
Melanoma
CML Sickle Cell |
|
Hydroxyurea Toxicity
|
Bone marrow supression
Upset GI |
|
Etoposide Mechanism
|
G2 Specific agent that inhibits topoisomerase II and increases DNA degradation
|
|
Etoposide Uses
|
Small cell carcinoma of the lung
Prostate Testicular carcinoma |
|
Etoposide Toxicity
|
Myelosupression
Gi irritation Alopecia |
|
Prenisone Mechanism
|
May trigger apoptosis
|
|
Prednisone Uses
|
CLL
Hodgkin's lmphomas Autoimmune diseases |
|
Prednisone Toxicity
|
Cushing like symptoms
Immunosupression Cataracts Acne Osteoporosis HTN peptic ulcers hyperglycemia psycosis |
|
Tamoxifen, Raloxifen Mechanism
|
Receptor antagonists in breast, agoinists in the bone- blocks the binding of estrogen to estrogen recptor- positive cells
|
|
Tamoxifen, Raloxifen Uses
|
Breast Cancer- also useful in preventing osteoporosis
|
|
Tamoxifen, Raloxifen Toxicity
|
Increased risk of endometrial carcinoma only with tamxifen
Hot flashes |
|
Trastuzumab (herceptin) Mechanism
|
Monoclonal antibody against the HER-2
Antibody dependent cytotoxicity |
|
Trastuzumab Uses
|
Metastatic breast cancer
|
|
Trastuzumab Toxicity
|
Cardiotxicity
|
|
Imatinib (Gleevec) Mechanism
|
Thyrosin kinase inhibitor for philadelphia chromosome- bcr-abl
|
|
Imatinib Use
|
CML
GI Stromal Tumors |
|
Imatinib Toxicity
|
Fluid retention
|
|
Vincristine/ Vinblastine Mechanism
|
M-Phase specicfic alkaloids that bind to tubulin and block the olymerization of microtubeules.
|
|
Vincristine/ Vinblastine Uses
|
Lymphoma
Wilm's tumor Choriocarcinoma |
|
Vincrisitine/ Vinblastine Toxicity
|
Vincristine- neurotoxicity, paralytic ileus
|Vinblastine- bone marrow supression |
|
Paclitaxel and other taxols mechanism
|
M phase specific agent that binds to tubulin and hyper stabilizes polymerized microtubutles so that mitotic spindle cannot break
|
|
Paclitaxel and other taxol uses
|
Ovarian and breast carcinomas
|
|
Paclitaxel and other taxols toxicity
|
Myelosupression and hypersensitivity
|